A Randomized, Open Label, Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LFG316 in Patients With Transplant Associated Microangiopathy After Hematopoietic Precursor Cell Transplantation
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Tesidolumab (Primary)
- Indications Thrombotic microangiopathy
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 18 Mar 2019 According to European Clinical Trials Database record the trial has been completed in UK - MHRA
- 28 Sep 2017 Status changed from recruiting to discontinued.
- 06 Jul 2017 This trial has been Discontinued in France, according to European Clinical Trials Database record.